#USA #Palo Alto #TMS #AMPA #Target Lock

Ampa's Groundbreaking Target Lock Feature: Revolutionizing TMS Treatment

In an era where mental health treatment is more crucial than ever, Ampa, a trailblazer in neurotechnology, has unveiled an innovative feature called 'Target Lock'. This cutting-edge tool aims to enhance the precision and consistency of transcranial magnetic stimulation (TMS) treatments across clinics nationwide. The announcement, made on October 27, 2026, marks a significant leap forward in making mental health therapies more accessible and effective.

Understanding Target Lock

Target Lock is a proprietary innovation incorporated into the Ampa One system, a TMS device that is FDA-cleared for treating adult patients suffering from Major Depressive Disorder. This feature utilizes a combination of embedded camera technology and a Neuronavigation Cap that continuously monitors the positioning of the treatment coil. If the coil deviates from its intended target during a session, the system automatically pauses treatment, allowing clinicians to readjust the coil back into the correct position.

Dr. Don Vaughn, co-founder and CEO of Ampa, expressed his enthusiasm about Target Lock, stating, "This is an exciting next step forward in making TMS easier to deliver at scale. By helping clinicians offer TMS with greater precision and ease, we are building confidence in the ability of Ampa One to be adopted by a broader range of practitioners, ultimately benefiting more patients."

The Impact on Clinical Practice

One of the primary challenges that clinics face when administering TMS is the potential for human error. Patients can inadvertently shift positions during treatment, leading to misalignment of the coil and ineffective stimulation. Dr. Owen Scott Muir, Chief Science Officer and co-founder of Radial Health, emphasized the importance of this new feature: "Target Lock provides our team with an objective tool to support operators as they monitor treatment delivery. It reinforces the correct positioning of the coil while integrating technology and proper training."

Target Lock not only mitigates errors but also empowers clinicians by providing real-time feedback during sessions. This level of oversight helps maintain the effectiveness of the treatment, ensuring that patients receive the best possible care without unnecessary interruptions.

A Step Towards Better Access

Ampa's commitment to improving TMS technology aligns with its overarching mission of enabling a billion remissions from mental and neurological disorders. By reducing operational burdens and simplifying treatment delivery, the introduction of Target Lock facilitates a more scalable application of TMS, aligning with the needs of modern clinical practices.

The Ampa One system, available by prescription only, is offered via a monthly subscription model, eliminating hefty upfront capital costs and per-treatment fees. This innovative approach not only promotes accessibility for clinics but also increases the potential reach of advanced TMS therapy to a wider patient demographic.

Conclusion

As Ampa continues to evolve and integrate technology into mental health treatments, the release of Target Lock represents a substantial advancement in neuromodulation therapy. By enhancing the precision and consistency of TMS, Ampa is paving the way for a future where effective mental health treatments are available to all who need them, streamlining the practices of clinicians while safeguarding patient outcomes. For those interested in learning more about Ampa and its innovative solutions, further information can be found at ampahealth.com.